BioQ Pharma Receives Australian Regulatory Approval for Ropivacaine ReadyFusOR

SAN FRANCISCO, Mar. 14, 2017: BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Ropivacaine ReadyFusOR for the treatment of post-surgical pain in adults via continuous peripheral nerve block and continuous wound infiltration. With well over two million surgical procedures annually, the market opportunity for post-surgical pain therapies in Australia is estimated to be more than A$500 million. The Ropivacaine ReadyFusOR is a disposable ready-to-use, single use infusion product, which is pre-filled by the manufacturer with 0.2% Ropivacaine, a non-narcotic local anesthetic. It is a self-contained drug and administration system for delivery at the point of care, activated by a single touch. The Ropivacaine ReadyFusOR contains a unit-dose of the sterile drug and is hermetically sealed until time of use. Josh Kriesel, President and CEO of BioQ Pharma, commented, “We look forward to launching Ropivacaine ReadyFusOR in Australia in the near-term. There is a need for completely ready-to-use pharmaceutical products that can help avoid the filling errors and breaches in sterility commonly associated with conventional elastomeric pumps and other post-operative pain treatments.” Walter Cleymans, Chief Commercial Officer of BioQ Pharma, stated, “Ropivacaine ReadyFusOR will minimize the number of hands that touch the drug en route to the patient, while enabling the opportunity for early mobility and discharge with a well-known local anesthetic.” BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services. Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Walter Cleymans Vice President Europe Phone: +32 474 (053) 253 Media: Stephanie Carrington Integrated Corporate Relations, Inc (ICR) [email protected] 646-277-1282 Back to News Company Board of Directors Management Medical Advisors Strategic Advisors Careers About Invenious ™ Safety Sterility Value Convenience Invenious ™ for manufacturers Benefits Experience Products & Pipeline Ropivacaine ReadyfusOR® invenious™/propofol Partners Sandoz Stada Cipla Lee's Pharm Galen See More... BioQ Pharma 1325 Howard Street San Francisco, CA 94103 BioQ Pharma B.V. Amelia Earhartlaan 17 9051 Sint-Denijs-Westrem Belgium Contact Us Business Development Privacy Policy Terms of Use Sitemap © 2019 BioQ Pharma. All Rights Reserved. About Invenious™ Invenious™ for Pharma Companies Products & Pipeline Partners Company Board of Directors Management Medical Advisors Strategic Advisors Careers News Contact

The release as fetched from its publisher. bioqpharma.com ↗